Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26306010 | 0.72 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPT | |
| SCHEMBL26556221 | 0.65 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL21675467 | 0.64 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL18812046 | 0.60 | RIPK1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL21372045 | 0.58 | ALDH1A1 (0.59) | ALDH1A1LMNAMAPT | |
| SCHEMBL8608128 | 0.55 | ALOX5 (0.45) | ALDH1A1LMNA | |
| SCHEMBL1408404 | 0.54 | — | — | |
| SCHEMBL25741926 | 0.54 | — | — | |
| SCHEMBL14982037 | 0.54 | MEN1 (0.45) | ALDH1A1LMNAMEN1CYP1A2KMT2A | |
| SCHEMBL21728723 | 0.53 | SMN1; SMN2 (0.43) | ALDH1A1LMNAMAPTMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | ALDH1A1 4794/4885LMNA 825/4885MAPT 4294/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | ALDH1A1 4794/4885LMNA 825/4885MAPT 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.